- FDA Accepts Journey Medical’s NDA for DFD-29 for Rosacea Dermatology Times
- Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting Yahoo Finance
- FDA accepts NDA for Journey Medical’s DFD-29 The Pharma Letter
- Journey Medical’s new rosacea drug application accepted by FDA By Investing.com Investing.com
- Journey Medical reports positive Phase 1 trial results for rosacea treatment By Investing.com Investing.com
Read More: FDA Accepts Journey Medical’s NDA for DFD-29 for Rosacea – Dermatology Times